1. Home
  2. ICUCW vs OC Comparison

ICUCW vs OC Comparison

Compare ICUCW & OC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
    SELLHOLDBUYas of 2024 years ago
  • OC
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • ICUCW N/A
  • OC 1938
  • Country
  • ICUCW United States
  • OC United States
  • Employees
  • ICUCW 12
  • OC N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • OC Industrial Machinery/Components
  • Sector
  • ICUCW Health Care
  • OC Industrials
  • Exchange
  • ICUCW Nasdaq
  • OC Nasdaq
  • Market Cap
  • ICUCW N/A
  • OC N/A
  • IPO Year
  • ICUCW 2021
  • OC N/A
  • Fundamental
  • Price
  • ICUCW $0.03
  • OC $134.14
  • Analyst Decision
  • ICUCW
  • OC Buy
  • Analyst Count
  • ICUCW 0
  • OC 13
  • Target Price
  • ICUCW N/A
  • OC $202.42
  • AVG Volume (30 Days)
  • ICUCW N/A
  • OC 1.1M
  • Earning Date
  • ICUCW N/A
  • OC 04-23-2025
  • Dividend Yield
  • ICUCW N/A
  • OC 2.06%
  • EPS Growth
  • ICUCW N/A
  • OC N/A
  • EPS
  • ICUCW N/A
  • OC 7.37
  • Revenue
  • ICUCW N/A
  • OC $10,975,000,000.00
  • Revenue This Year
  • ICUCW N/A
  • OC N/A
  • Revenue Next Year
  • ICUCW N/A
  • OC $2.40
  • P/E Ratio
  • ICUCW N/A
  • OC $18.20
  • Revenue Growth
  • ICUCW N/A
  • OC 13.41
  • 52 Week Low
  • ICUCW N/A
  • OC $126.15
  • 52 Week High
  • ICUCW N/A
  • OC $214.53
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • OC 32.53
  • Support Level
  • ICUCW N/A
  • OC $137.92
  • Resistance Level
  • ICUCW N/A
  • OC $147.45
  • Average True Range (ATR)
  • ICUCW 0.00
  • OC 4.75
  • MACD
  • ICUCW 0.00
  • OC 0.08
  • Stochastic Oscillator
  • ICUCW 0.00
  • OC 31.74

Stock Price Comparison Chart: ICUCW vs OC

ICUCW
OC
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April020406080100120140160180200220ICUCW VS OC

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use